Effectiveness of biotherapy with somatostatin analogues in the treatment of a patient with carcinoid syndrome with neuroendocrine tumors of the pancreas

Neuroendocrine tumors are nowadays diagnosed quite often and it is important to know that they often lead to carcinoid syndrome due to the production of serotonin by the cells. Clinical manifestations of carcinoid syndrome (flushes, erythema of the skin of the face, neck, chest, development of diarrhea, etc.) significantly reduce the quality of life of patients. Personalized medicine implies a constant search for new means and ways to optimize the diagnosis of diseases and treatment of each patient. The subject of this article is a specific clinical case of carcinoid syndrome in pancreatic NET. The aim of the work is to analyze the effectiveness of biotherapy with somatostotin analogues in the treatment of carcinoid syndrome in pancreatic NET on the example from clinical practice. When discussing the problems of treatment of a patient with carcinoid syndrome in pancreatic NEТ the results of laboratory tests, data of various methods of diagnostics and treatment are used. To confirm the effectiveness of biotherapy with somatostotin analogs, visual material (photos of the patient in dynamics) is offered.

1. Imyanitov E.N. Epidemiologia et biologia de tumoribus neuroendocrinis. Oncologia practica, 2005, Vol. 6, No. 4, рр. 202–205 (In Russ.).

2. Pearse A.G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept // J. Histochem. Cytochem. 1969. Vol. 17. P. 303–313.

3. Kim M. et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening // Nat. Commun. 2019. Vol. 10. Р. 3991.

4. Lei Y., Feng H., Qiang H., Shang Z., Chang Q., Qian J., Zhang Y., Zhong R., Fan X., Chu T. Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study // Lung Cancer. 2020. Vol. 146. Р. 244–251.

5. WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine tumours. Lyon (France): International Agency for Research on Cancer; 2022 (WHO classification of tumours series, 5th ed.; vol. 8).

6. Gurevich L.E., Voronkova I.A., Marova E.I., Lapshina А.М., Britvin T.A., Kamerdus I.V. Orci et morphologicae notae ACTH-absconditorum tumores variorum locorum cum syndrome Cushing ectopic. Fusce aliquet arcu nisl, 2017, Vol. 45, No. 4, рр. 289–301 (In Russ.).

7. Gorbunova V.A. Neuroendocrinarum tumores. Principia generalia diagnosis et curationis. Moscow: Instructio domus «Kodeks», 2015. 455 р. (In Russ.).

8. Murray N., Salgia R., Fossella F.V. Targeted molecules in small cell lung cancer // Semin. Oncol. 2004. Vol. 31 (Suppl. 1). P. 106–111.

9. Kogonia L.M., Markarova E.V., Gurevich L.E., Bondarenko E.V. The effect of chemotherapy on the quality of life of a patient with NET of the cecum. Palliative Medicine and Rehabilitation, 2023, No. 1, pp. 33–35 (In Russ.).

10. Markarova E.V., Kogonia L.M., Gurevich L.E., Bondarenko E.V., Kalinin D.V. Successful use of biotherapy with somatostatin analogues in the treatment of a patient with multiple endocrine neoplasia type 1. Medical Council, 2023, Vol. 17, No. 11, pp. 166–171 (In Russ.).